Question 1

What is the catalog number for NCX1 Antibody [C23J23]?

Accepted Answer

The catalog number for NCX1 Antibody [C23J23] is F2381-100uL*2.

Question 2

What sizes are available for NCX1 Antibody [C23J23]?

Accepted Answer

NCX1 Antibody [C23J23] is available in the following size(s): 2x 100 μL.

Question 3

Is NCX1 Antibody [C23J23] in stock?

Accepted Answer

NCX1 Antibody [C23J23] is currently made to order / not held in immediate stock. Contact us for lead time.

Question 4

Who manufactures NCX1 Antibody [C23J23]?

Accepted Answer

NCX1 Antibody [C23J23] is manufactured by Bimake.

Question 5

What is the estimated delivery time for NCX1 Antibody [C23J23]?

Accepted Answer

Estimated delivery time for NCX1 Antibody [C23J23] is approximately 15 business day(s), depending on your location.

Question 6

What do I do if this product arrives with reduced ice or a damaged cold-chain package?

Accepted Answer

Report this to us immediately with photos and your order reference. Our specialists will assess whether the product is still usable given the cold-chain interruption, and will arrange a replacement or credit if it isn’t.

Question 7

What host species was used to raise this antibody?

Accepted Answer

The host species used in production is listed under product specifications on the datasheet, and is relevant when selecting a compatible secondary antibody for your assay.

Question 8

What is the difference between this product and a similar catalogue number?

Accepted Answer

Differences typically involve clone, conjugate, host species, or validated applications. Compare the respective datasheets, or contact us with both catalogue numbers for a direct comparison.

NCX1 Antibody [C23J23]

Product Specifications

Synonyms

Additionnal Information

Storage Conditions

Frequently Asked Questions

Explore Other Products

CXCL17 Antibody

CXCL17 Antibody

CXCL17 Antibody

CD5 (CD5/54/F6), CF594 conjugate, 0.1mg/mL

MSK1 (RPS6KA5) (NM_182398) Human Over-expression Lysate

ACTRT1 Human Gene Knockout Kit (CRISPR)